Pericarditis Drugs Market Size - By Type, By Drug Class, By Route of Administration, By Gender, By End Use - Global Forecast, 2025 - 2034

Pericarditis Drugs Market Size

The global pericarditis drugs market was estimated at USD 4.1 billion in 2024. The market is expected to grow from USD 4.3 billion in 2025 to USD 7.4 billion in 2034, at a CAGR of 6.2%. The rising incidence of cardiovascular disease worldwide increases the demand for targeted anti-inflammatory drugs, contributing to market growth.

According to the World Heart Federation, there are more than 20.5 million cases worldwide annually, and deaths from the disease have increased by 60% globally over the last 30 years. Cardiovascular diseases were the leading cause of death in 2021, with 4 in 5 deaths occurring primarily in low- and middle-income countries.
 

The pericarditis drugs market includes various drugs used for the treatment of acute and chronic pericarditis. These drugs primarily aim to reduce pain and inflammation associated with the condition. Commonly used medications include nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine and corticosteroids. Moreover, the major players operating in the market include Kiniksa Pharmaceuticals, Takeda Pharmaceuticals, AstraZeneca, Bayer, and Novartis. Typically, the pericarditis drugs are used as advanced drug management systems across hospitals and cardiology clinics.
 

The market increased from USD 3.5 billion in 2021 to USD 3.9 billion in 2023. This upward trajectory was fuelled by rising prevalence of cardiovascular disease, growing shift toward digital health platforms with the integration of AI-diagnostics and remote monitoring further escalating the market growth.
 

The rising cases of recurrent pericarditis are driving market demand, as this condition is more common than other types of pericarditis. The National Institutes of Health (NIH) reports that recurrent pericarditis affects 15-30% of patients, and this rate can climb to 50% in people who have experienced previous episodes, including those who have been treated with non-steroidal anti-inflammatory drugs and corticosteroids, or those with non-idiopathic conditions.
 

Surge in technological advancement in medical treatments and increasing use of combination therapies for the treatment of pericarditis is stimulating market growth. Moreover, the prevalence of pericarditis cases in male is found to be higher than that of female. The higher hormonal influence in male, higher testosterone may enhance the inflammatory response to viral infections which is a common cause for the disease in men. According to Cleveland Clinic, pericarditis affects men more frequently, particularly those between 16-65 years of age. Each year, about 28 in every 100,000 people develop pericarditis. The condition, specifically acute idiopathic pericarditis, tends to occur more often in men.
 

As healthcare infrastructure continues to expand in emerging countries, people are becoming more aware of cardiac health, which is driving market growth. The increasing elderly population, who are at higher risk of pericarditis and its complications, contribute to market growth. Scientists and researchers are actively involved in research and development activities for the development of new therapeutic approaches, opening up more possibilities in the market.
 

The integration of AI and machine learning in drug discovery processes is stimulating the efficiency of new pericarditis treatments. Growing investments in clinical trials, rising demand for personalized medicine along with the emergence of targeted therapies are together contributing to market growth. Moreover, the increasing focus on patient compliance and the development of patient specific drug delivery systems are increasing market growth.
 

Government initiatives and public-private partnerships aimed at digitizing healthcare infrastructure are further advancing the market. These efforts are integrating tele-medicine with management of pericarditis, enabling exposure and awareness in remote areas, and improving health access, particularly in emerging regions. As a result, the market is witnessing a significant transformation, with digitalization playing a pivotal role in addressing the awareness of cardiac disorders and enhancing patient outcomes.
 

Pericarditis Drugs Market Trends

The market experiences a significant transformation, which is driven by both macro-level healthcare shifts and micro-level healthcare innovations in immunology and patient-centric care and compliance. The increasing cardiovascular diseases continue to rise globally, that raises the demand for targeted therapies for inflammation caused due to pericardial is stimulating the market growth. The market is increasingly shifting due to the convergence of biologics, precision medicine, and digital health integration, with a strong goal to improve patient outcomes and reduce the recurrence cases.
 

• The rising use of interleukin inhibitors such as rilonacept, are gaining attention which are used for treating recurrent pericarditis. These therapies provide targeted anti-inflammatory action, reducing recurrence and improving quality of life. Clinical trials for pericarditis are expanding the use of biologics in patients who are resistant to NSAIDs and colchicine. Many hospitals, particularly in North America and Europe, have already adopted biologics for colchicine-intolerant patients.
   
• The increasing shift toward precision medicine is enabling adoption to treatment plans based on patient demographics, severity of disease and genetic markers. The use of cardiac MRIs and CRP-level monitoring are increasingly used for therapy guidance decisions. This approach is particularly critical for the management of autoimmune-related pericarditis, which affects a growing segment of patients.
   
• The growing trend of using telehealth platforms along with remote cardiac monitoring into pericarditis care, especially for follow-up and chronic disease management, drives the growth of the market. In addition, the increased use of telecardiology tools in many cardiac centers to monitor symptoms along with recurrence risk and medication adherence. Such platforms are important in rural regions, where the access to specialists is limited.
   
• Lastly, the recurrent pericarditis affects a major portion of patients after initial episodes, which increase the need for combination therapies that includes colchicine, NSAIDs and biologics. These doses are being optimized for the reduction of inflammation, prevention of recurrent cases and decreasing side effects.
   

Pericarditis Drugs Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

The market was valued at USD 3.5 billion in 2021. The market size reached USD 3.9 billion in 2023, from USD 3.7 billion in 2022.
 

Based on type, the market is categorized into acute pericarditis, recurrent pericarditis, chronic pericarditis, and other types. The acute pericarditis segment accounted for 46.1% of the market in 2024. The market growth is driven by rising incidence, improved diagnostic accuracy, and ability to be managed effectively across diverse healthcare environments. The segment is expected to exceed USD 3.3 billion by 2034, growing at a CAGR of 5.8% during the forecast period.
 

• The increasing shift towards early diagnosis in cardiovascular care is escalating the adoption of acute pericarditis management strategies. Such approaches are used as an alternative to chronic care by timely symptom relief, inflammation control, and prevention of complications.
   
• Acute pericarditis has a recurrence rate of 20% to 30%, according to a study by ScienceDirect. Up to 50% of patients who experience one recurrence develop multiple episodes of pericarditis.
   
• The rising prevalence of viral infections and the growing emphasis on outpatient cardiac care are further stimulating the demand for acute pericarditis solutions. These strategies utilize non-invasive diagnostics and first-line anti-inflammatory therapies, reducing the need for hospitalization and intensive monitoring, even in resource-constrained settings.
   
• On the other hand, recurrent pericarditis segment is expected to grow with a CAGR of 6.6%. The growth of this segment can be attributed to increasing cases and awareness of recurrence risks, demand for long-term management solutions, and development of biologic therapies. According to NIH, recurrent pericarditis is the most common complication following acute pericarditis, affecting 15-30% of patients, with incidence rates reaching up to 40-50% in some cases.
   
• On the other hand, chronic pericarditis segment is expected to grow with a CAGR of 6.1%. The growth of this segment is stimulated by its complex pathology, need for sustained care, and rising demand for personalized treatment and advanced imaging techniques.
   

Based on the drug class, the pericarditis drugs market is segmented into nonsteroidal anti-inflammatory drugs, colchicine, IL-1 inhibitors/biologics, and other drug classes. The nonsteroidal anti-inflammatory drugs segment accounted for the highest market share of 49.3% in 2024 due to their effectiveness in inflammation control, broad therapeutic applicability, and strong support for managing acute and recurrent pericarditis across diverse patient populations.
 

• The nonsteroidal anti-inflammatory drugs (NSAIDs) segment holds a dominant share in the market, stimulated by widespread use as first-line therapy for inflammation and pain management. According to NIH, over 30 million people globally consume NSAIDs daily. In U.S., healthcare providers generated more than 111 million NSAID prescriptions annually, representing approximately 60% of the country's over-the-counter analgesic market.
   
• The rising incidence of acute and recurrent pericarditis globally, especially in developed regions, is increasing demand for effective anti-inflammatory treatments that can control symptoms and prevent complications.
   
• The growing adoption of colchicine alongside nonsteroidal anti-inflammatory drugs is changing treatment strategies in pericarditis care. This reduces inflammation, prevent relapses and are increasingly preferred in hospital and outpatient settings.
   
• The increasing accessibility and affordability of nonsteroidal anti-inflammatory drugs drive higher adoption rates, supported by expanding healthcare infrastructure and growing awareness of cardiovascular diseases.
   
• The integration of dual-drug regimens into treatment plans enhances therapeutic efficacy, enabling more personalized approaches for pericarditis management across healthcare systems.
   
• IL-1 inhibitors/biologics are experiencing rapid growth due to increasing demand for emerging therapies targeting recurrent pericarditis, unmet clinical needs, and growing interest in precision medicine.
   
• Healthcare providers seeking to improve long-term outcomes for pericarditis patients have prompted pharmaceutical companies to develop advanced biologic solutions that reduce recurrence risks.
   

Based on route of administration, the pericarditis drugs market is segmented into oral and parenteral. The oral segment accounted for the highest market share of 58.2% in 2024 due to its accuracy in systemic drug absorption, suitability for anti-inflammatory agents such as NSAIDs and colchicine, and compatibility with long-term outpatient treatment protocols.
 

• The oral segment is gaining significant traction due to its superior ability to deliver anti-inflammatory agents with consistent absorption and simplified dosing regimens.
   
• Oral medications are easy to administer compared with other routes such as parenteral, causing higher patient compliance. Adherence to oral therapies is significantly higher compared to injectable treatment, also patients prefer taking a pill at home rather than visiting healthcare facilities for injections.
   
• Oral medications are more cost-effective than parenteral treatments, as they require less infrastructure for administration and fewer healthcare resources.
   
• On the other hand, parenteral therapies are gaining significant market traction due to their critical role in emergency care and inpatient settings, where fast-acting relief and precise dosing are essential for managing severe or refractory pericarditis cases.
   

Based on the gender, the pericarditis drugs market is segmented into male and female. The male segment accounted for the highest market share of 64.9% in 2024 due to higher prevalence of cardiovascular conditions, greater susceptibility to recurrent pericarditis, and strong clinical response to anti-inflammatory therapies across varied age groups.
 

• The male segment holds a dominant share in the market due to the higher prevalence of cardiovascular conditions and increased susceptibility to recurrent pericarditis.
   
• In 2024, this segment dominated the global market, driven by strong clinical response to NSAIDs and colchicine and higher diagnosis rates among the male population. For instance, as per the report published by the American Heart Association/American Stroke Association, pericarditis prevalence in men was approximately 64.9%, highlighting a gender-based diagnostic trend that significantly influenced treatment demand and market growth.
   
• On the other hand, the female segment is anticipated to expand quickly, driven by increasing awareness, improved diagnostic capabilities, and a growing recognition of gender-specific pericarditis. As personalized medicine becomes more prevalent, female patients are expected to benefit from tailored therapies that offer enhanced efficacy with reduced toxicity, thereby accelerating market growth in this demographic.

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the pericarditis drugs market is categorized into hospitals and clinics, homecare settings and other end users. The hospitals and clinics segment accounted for the highest market share of 55.2% in 2024 due to their precision in workflow handling, compatibility with diverse patient volumes, and integration in cloud-supported diagnostic and treatment systems.
 

• The segment is growing due to the rising prevalence of cardiovascular conditions such as acute and recurrent pericarditis, along with the need for professional diagnosis and specialized care, which is increasing the dominance of hospitals and clinics. Patients with chest pain and inflammation are seeking treatment in clinical settings for access to advanced cardiac resources.
   
• The increasing chronic and recurrent pericarditis cases, which need continuous medical attention and complex drug regimens, are contributing to the increasing number of visits to hospitals and clinics. As cardiovascular diseases are the leading causes of death worldwide, this creates consistent demand for specialized care. The presence of trained cardiologists and emergency facilities in hospitals ensures better treatment outcomes, thereby contributing market growth.
   
• Moreover, hospitals and clinics are the primary centers for prescribed drugs and advanced therapies, such as intravenous anti-inflammatory agents and combination drug for severe cases. These settings offer treatment protocols, monitoring services, and rehabilitation, which are important for long-term care. The growing number of hospital admissions for cardiac complications further escalate market growth.

Looking for region specific data?

Download Free PDF

The North America pericarditis drugs market dominated the global market with a market share of 46.6% in 2024.
 

• The market is stimulated by the rising prevalence of pericardial disorders and increasing spending on cardiovascular care. In addition, advancements in drug development technologies with the growing focus on treatment efficiency also support market growth.
   
• North America particularly U.S. has one of the highest per capita healthcare expenditures globally. This ensures greater access to diagnostics, specialty care and biologic therapies for pericarditis patients.
   
• In addition, hospitals, and clinics in this region are increasingly using updated American Heart Association (AHA) and the American College of Cardiology (ACC) guidelines which promote evidence-based pharmacological management of pericarditis including colchicine and IL-1 inhibitors.
   

The U.S. pericarditis drugs market was valued at USD 1.5 billion and USD 1.6 billion in 2021 and 2022, respectively. The market size reached USD 1.8 billion in 2024, growing from USD 1.7 billion in 2023.
 

• The increasing prevalence of cardiovascular diseases in the U.S. drives the demand for pericarditis treatment options. According to the CDC, a heart attack occurs every 40 seconds. Similarly, as per the NIH reports approximately 34,441 patients in the U.S. annually suffer from pericarditis due to inadequate response to conventional therapies. This growing patient population emphasizes the need for specialized care, thereby contributing to market growth.
   
• The rising incidence of recurrent pericarditis in the U.S. population drives market growth. According to the American Heart Association Journals, approximately 30% of patients experience recurrent pericarditis within 18 months.
   
• Moreover, the growing awareness of heart health among the U.S. population contributes to market expansion. Surveys indicate that a significant portion of the population considers cardiovascular health essential to overall well-being. This increased awareness of inflammatory heart conditions drives the demand for targeted therapies and treatment access.
   

Europe pericarditis drugs market accounted for USD 969 million in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• Rising awareness and adoption of advanced cardiovascular therapies in the region, along with increasing government initiatives to strengthen healthcare infrastructure, is anticipated to spur growth in the market in Europe.
   
• Moreover, advancements in drug technologies, such as biologics and targeted anti-inflammatory agents, along with the introduction of scalable and cost-effective treatment options, boost the requirement for pericarditis drugs across the European region.
   
• Also, the presence of key pharmaceutical companies in the region strengthens the market. These companies actively participate in innovation through the development of next-generation therapies, expanded clinical research, and partnerships with cardiology associations, thereby advancing market growth.
   

Germany pericarditis drugs market is anticipated to witness considerable growth over the analysis period.
 

• The increasing cases of cardiovascular diseases in Germany contribute to the rising demand for pericarditis drug treatment, particularly among adults and elderly populations. The growing number of pericardial disorder cases emphasizes the need for effective drugs and care systems to manage acute and recurrent pericarditis.
   
• The expansion of hospital and specialty care networks, supported by government initiatives, drives market growth. Germany's advanced healthcare infrastructure and favorable policies enable access to cardiac care, including biologics and combination therapies. This accessibility increases the demand for pericarditis drugs across clinical settings.
   

The Asia Pacific pericarditis drugs market is anticipated to grow at the highest CAGR of 6.7% during the analysis timeframe.
 

• The market in the Asia Pacific region is growing rapidly due to the rise in cardiovascular disease cases, increasing digital health awareness, and the improvement of healthcare infrastructure across both urban and rural hospitals and clinics.
   
• Countries such as China, India, and Japan are adopting pericarditis treatment solutions at a faster rate due to surge in demand for efficient care delivery, government-led digital health initiatives, and the rise in cloud-based platforms supporting multi-specialty practices.
   
• Additionally, the rapid increase in the number of cardiac care centers and healthcare IT providers, along with increasing government policies aimed at expanding digitalization and integrating cardiovascular treatment into national health strategies, contributes to the rapid growth of the market in the region.
   

China pericarditis drugs market is predicted to grow significantly over the forecast period.
 

• The growing awareness of cardiovascular health is stimulating the adoption of pericarditis drugs treatment to increase patient education and engagement.
   
• Moreover, the high prevalence of idiopathic pericardial disorders further escalates the demand for effective therapies to improve the efficiency of cardiovascular care.
   
• Additionally, the high cases of early post operative constrictive pericarditis further escalate the demand for novel therapeutic interventions.
   
• The low rate of early diagnosis and preventive cardiac visits highlights the need for improved outreach and screening programs. Patients commonly seek treatment after experiencing severe symptoms, providing awareness for the importance of campaigns and structured pathways to improve outcomes.
   

Brazil is experiencing significant growth in the Latin America pericarditis drugs market due to rising prevalence of pericarditis and cardiovascular inflammation along with growing awareness and diagnosis through advanced imaging.
 

• The high prevalence of cardiovascular conditions in adolescents and adults emphasizes increasing need of cardiac healthcare. This increasing shift toward advanced treatment solutions, such as rising demand of colchicine and IL-1 inhibitors drives the growth of the market.
   
• Government-led initiatives promoting healthcare digitalization, including electronic health records, cloud-based systems, and data security compliance, are accelerating the adoption of pericarditis treatments across public and private healthcare facilities.
   
• Additionally, programs for expanding access to cardiovascular care and integrating artificial intelligence infrastructure in rural and urban areas are further strengthening the market's growth.
   

Saudi Arabia pericarditis drugs market is poised to witness substantial growth in the Middle East and Africa market during the forecast period.
 

• Healthcare digitalization investments under Saudi Arabia's Vision 2030 are accelerating the transition from manual to automated platforms in the market.
   
• The improved access to cardiovascular care across urban and rural regions is driving the demand for advanced pericarditis treatment solutions. The rising patient numbers, particularly among high-risk and elderly populations, are prompting hospitals and clinics to implement cloud-based systems for diagnosis, treatment planning, and patient monitoring.
   
• Government incentives for critical hospital cases and telehealth services are increasing the demand across public and private healthcare facilities, complementing the ongoing modernization of healthcare infrastructure.
   

Pericarditis Drugs Market Share

Leading companies such as Pfizer, Novartis, Merck, Bayer and Kiniksa Pharmaceuticals together hold ~55% of the market share in the global market. The key players in the market maintain dominance through robust drug portfolios, strategic partnerships, regulatory compliance, and continuous innovation. Kiniksa Pharmaceuticals holds a strong competitive advantage due to its drug ARCALYST, which is widely adopted across hospitals and specialty clinics for its targeted IL-1 inhibition in recurrent pericarditis.
 

Novartis, known for its cardiovascular and immunology expertise, leverages biologic innovation and enterprise-level scalability to meet the needs of chronic and recurrent pericarditis patients. Meanwhile, Merck’s immunomodulatory treatments offer integration with broader cardiac care protocols, making them as the preferred choice for healthcare providers focused on long-term outcomes and safety.
 

Companies such as Cipla and Dr. Reddy’s Laboratories are also using competitive pricing strategies for anti-inflammatory solutions, offering affordable options for smaller hospitals for robust efficacy. Vendors address market gaps by launching AI-powered diagnostics and patient monitoring tools.
 

New entrants such as Kiniksa Pharmaceuticals are disrupting the market with therapies built around IL-1 inhibition, offering biologic solutions tailored for modern inflammatory care. Kiniksa established itself as a strong competitor in the market after expanding its presence in North America and Europe.
 

Pericarditis Drugs Market Companies

Few prominent players operating in the pericarditis drugs industry includes:
 

• AstraZeneca
• Bayer
• Cipla
• Dr. Reddy's Laboratories
• Eli Lilly
• Fosun Pharma
• Kiniksa Pharmaceuticals
• Merck
• Novartis
• Pfizer
• Sun Pharmaceuticals
• Takeda Pharmaceuticals
• Teva Pharmaceuticals
• Zydus Cadila
  
   
• Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals has a dominant position in the pericarditis treatment space due to its innovative biologic therapy, ARCALYST, specifically for recurrent pericarditis. By targeting IL-1 mediated inflammation, ARCALYST offers a breakthrough in reducing flare-ups and improving patient outcomes. Kiniksa’s deep clinical expertise, focus on rare inflammatory diseases, and commitment to precision medicine make it a trusted choice for specialists managing complex cardiac inflammation.
 

• Bayer

Bayer’s global cardiovascular expertise to deliver dependable NSAID-based therapies for acute pericarditis. Its long-standing reputation in anti-inflammatory care, combined with ongoing research into combination regimens, positions Bayer as a dependable provider for frontline treatment. By integrating pericarditis management into broader cardiac care pathways, Bayer ensures continuity, safety, and accessibility across healthcare systems.
 

• Pfizer

Pfizer brings scale and accessibility to the pericarditis market through its well-established anti-inflammatory and colchicine-based therapies. Pfizer’s emphasis on real-world evidence, patient adherence tools, and integration with digital health platforms makes it a preferred partner for hospitals and clinics treating both acute and chronic cases.
 

• Takeda Pharmaceuticals

Takeda’s includes next-generation agents for reducing steroid dependency and increasing patient quality of life, with the industry's shift toward personalized and sustainable care. Takeda Pharmaceuticals focuses on immunomodulatory and biologic therapies tailored for inflammatory conditions like pericarditis. Its USP lies in advanced drug delivery systems, AI-enhanced clinical research, and strategic investments in long-term care solutions.
 

Pericarditis Drugs Market Industry News

• In April 2025, Scilex received FDA approval for orphan drug for colchicine in the treatment of pericarditis. The approval was for its liquid oral formulation, Gloperba, for improving dosing flexibility and patient accessibility. This regulatory expanded Scilex’s therapeutic portfolio within the rare cardiovascular disease segment.
   
• In March 2021, Kiniksa Pharmaceuticals received FDA approval for ARCALYST (rilonacept) as the first treatment for recurrent pericarditis. This expanded Kiniksa’s commercial portfolio in the cardiovascular immunology market.
   

The pericarditis drugs market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Acute pericarditis
• Recurrent pericarditis
• Chronic pericarditis
• Other types

Market, By Drug Class

• Nonsteroidal anti-inflammatory drugs
• Colchicine
• IL-1 inhibitors/biologics
• Other drug classes

Market, By Route of Administration

• Oral
• Parenteral

Market, By Gender

• Male
• Female

Market, By End Use

• Hospitals and clinics
• Homecare settings
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE